China approves its first COVID antibody treatment

Thursday, 09. December 2021 11:02

Chinese health authorities approved the use of the country's first COVID-19 antibody treatment developed by domestic company Brii Biosciences.

In a statement released on Thursday, Brii Bio said that their medicament reduced the hospitalization and death rate among patients with a high risk of contracting COVID-19 by 80%. China's National Medical Products Administration approved the drug's use in all people older than 12 who have mild COVID-19 symptoms.

Brii Bio has also applied for the treatment's approval in the United States, where companies such as Regeneron Pharmaceuticals and Eli Lilly already offer similar products. Commenting on the Omicron variant, Brii's CFO Li Ankang said that the drug's efficacy versus this mutation would be known in around two weeks.

Related Links: 
Baha Breaking News (BBN) / ND